







        
          
         
             
               
            
              
         
 
                  
                
              
               
             
 
                
               
               
      
 
         
                
               
               
                
           
 
               
              
                
                 
       
 





Prepared by the Institute for Healthcare Improvement (IHI)
 
Prepared for the Centers for Disease Control and Prevention (CDC)
 
A Framework to Reduce Inappropriate Antibiotic Utilization in Hospitals
The Centers for Disease Control and Prevention (CDC) and the Institute for Healthcare
Improvement (IHI) partnered in an effort to develop this conceptual model of key drivers for
reducing inappropriate antibiotic utilization. Content experts contributed to the development of
this robust driver diagram and change package with a recognition and emphasis on practicality
and ease of implementation in all hospitals..
“A driver diagram is a tool to help organize our theories and ideas in an improvement effort as
we answer what change can we make that will result in improvement? The initial driver diagram
for an improvement project might describe the descriptive theory of improved outcomes that can
then be tested and enhanced to develop a predictive theory. The driver diagram should be
updated throughout an improvement effort and used to track progress in theory buildingi.”
Pilot Testing: From September 2011 to June 2012, CDC and IHI worked with eight hospitals on
pilot testing the enclosed set of recommendations to assess the feasibility of implementation in
hospitals of varying size, acuity, and location. The Driver Diagram and Change Package were
modified based on that pilot testing.
How to Use The Driver Diagram and Change Package:
The Driver Diagram attempts to lay out the various processes that can lead to optimal antibiotic
use. The broad categories of these processes are referred to as Primary and Secondary
Drivers. The Change Package outlines a number of specific interventions that have either been
demonstrated to or experts believe will positively impact the drivers. The ultimate goal is to use
the interventions in the Change Package to “drive” improved antibiotic use.
We do not recommend that any facilty attempt to implement all of the interventions at
once. There are a large number of interventions outlined in the Change Package, and
attempting to implement too many at one time will likely create huge challenges. Rather, the
Change Package is meant to serve as a menu of options from which facilities can select specific
inerventions to improve antibiotic use.
 
                  
 
              
             
           
               
               
        
 
               
             
               
              




Selection of specific interventions to implement should be tailored to the areas that most
need improvement at each facility. Facilities should assemble a multi-disciplinary team of
physicians, pharmacists, nursing, microbiology and administration to discuss the aspects of
antibiotic use that are most in need of improvement. The team can then select specific
interventions from the Change Package to address those issues. It is important to select the
interventions that are most supported by clinical staff.
It is essential to monitor and measure. The Driver Diagram and Change Package come with
a Measurement Framework, which suggests various measures of antibiotic use that might be
useful to assess the effectiveness of improvements. Just as important is the measurement of
“small tests of change” to assess the implementation of interventions. Reviews of small
numbers of charts or discussions with clinicians can identify potential barriers to implementation.
2 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
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1. Identify clinical providers as champions to be thought leaders about 
antibiotic stewardship.
2. Work with administrators to ensure that they understand the rationale
and goals for stewardship programs and interventions so that they can
provide support (financial and non-financial).
3. Engage a physician champion and core team to enhance the focus of
antimicrobial stewardship into the current process of care. 
4. Bring disciplines together to improve communication and collaboration








• Infectious disease experts.
5. Consider having the multidisciplinary group perform a gap analysis of
antimicrobial use at the facility to identify priority areas for improvement. 
4 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
     












































    
   
  
 
   
 












   
  
      
   
  
    







   
    
   
  


















1. Develop standardized diagnostic criteria for identifying patients with signs and
symptoms suggesting specific types of infection (e.g., community acquired
pneumonia (CAP), urinary tract infection (UTI), skin/soft tissue infection (SSTI), 
bloodstream infection (BSI), sepsis etc).  These criteria should also clearly specify
situations when antibiotics are not indicated (e.g. non-infectious mimics of CAP). 
2. Develop evidence-based clinical pathways
ii
 that guide diagnostic testing and
treatment for these common infections. 
3. Consider a computerized decision support system to enable physicians to identify
















1. Utilize prompts for obtaining cultures in automated medication dispensing systems
available in ED, ICU, etc.
2. Develop processes to ensure cultures are properly and consistently ordered that 
include:
• Prompts on antibiotic orders or physician order entry to remind users to obtain
appropriate cultures;
• Culture prompts or default orders incorporated into standardized order sets for
various conditions (e.g., CAP, UTI, SSTI, BSI);
• Guidance on appropriate specimen type and culture common infections (e.g., 
CAP, UTI, SSTI, BSI);  
• Guidance on frequently inappropriate culturing practices (e.g., swabs of wounds, 
urine cultures from asymptomatic patients). 
3. Develop processes to ensure cultures are properly and consistently obtained that 
include:
• Protocols empowering/authorizing nursing staff to obtain cultures if other
providers fail to order them when starting antibiotics;
• Guidance on appropriate specimen collection for specific indications (e.g., 
number of blood cultures and volume of blood, cultures for anaerobic pathogens, 
rapid diagnostic tests);
• Visual cues in locations near antibiotic storage reminding staff to ensure cultures
have been obtained;
• Flags or other signal (at the bedside, in the electronic medical record (EMR), in
the chart) to make it apparent if cultures have not yet been obtained, and
checkboxes indicating that cultures have been obtained;
• A system to ensure cultures are obtained in patients transferred from the
emergency department (ED) to the intensive care unit (ICU) or ward.
4. Develop processes to ensure cultures are properly and promptly  transported and
processed.
5. Develop standards for and assess reliability of processes for ordering and obtaining
a culture for the following five steps: 
• Appropriate specimen; 
• Appropriate collection (i.e., before antibiotics were started);
• Appropriate labeling;
• Transport to lab (i.e., time from obtaining specimen to receipt in lab)
• Processing of specimen (i.e., time from receipt in lab to start of processing). 
5 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
     























   
  
 




    
  











     
   
    
 
    
  
   
 
   




















   
  
   
     
 
    
 








































1. Develop a list of agents that should generally not be combined and develop a
mechanism for pharmacy to flag these combinations for review (e.g., double
anaerobic coverage).   
2. Leverage the EHR with decision support at the point of care to trigger ABs with
overlapping activity or combinations not supported by GLs. 
3. Standardize a mechanism for review and follow-up of combinations of agents that 
are not recommended. 
4. Develop evidence-based guidelines for the specific conditions in which combination
therapy is recommended and what agents should be combined (based on local
formulary and patterns of resistance).  
• In general, use of combination therapy should be limited to empiric coverage of











1. Consider patient allergies when initiating or changing therapy.
2. Ensure that antibiotic allergies are obtained and documented in the medical record.  
Documentation should include the antibiotic and the type of reaction (e.g., 
anaphylaxis, rash etc).
3. Incorportate patient allergies as a required field in the EHR (ie:  nursing
assessment)
4. Ensure antibiotic allergy history distinguishes true allergies that would preclude use
(e.g., anaphylaxis) from adverse drug reactions (e.g., diarrhea).
•  Involve patient and family in identifying and confirming allergies;
• Consider testing for beta-lactam allergy to confirm antibiotic allergy.
6. Prominently flag medical record or computer order entry system to denote patient 
allergies to antibiotics.













1. Develop facility-specific guidance for diagnosing and treating infections and using
antibiotics.  
• Consider starting with most commonly treated infections and/or most commonly
used antibiotics and most common treatment errors (e.g., when anaerobic
coverage is needed); 
• Base the guidance on evidence as well as local susceptibility data and facility
formulary;
• Involve pharmacy and microbiology staff in developing and supporting antibiotic
selection guidance.
2. Imbed facility-specific guidance in evidence-based clinical pathways and order sets. 
3. Utilize the EHR with clinical decision support functionality to support antibiotic
selection.
4. Ensure that selection guidelines consider: 
• Site of infection;
• Pharmacokinectics/dynamics of the agent
• Pathogen(s) that is the most likely cause of the infection being treated and its
susceptibility profile in the hospital and community;
• Toxicity;
• Potentially complicating comorbid conditions (e.g. renal dysfunction); 
• Severity of the infection;
• Hospital formulary and cost.  
6 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
     





















    
   
     
   
  











    
 
  
    
  
    






    
 


























      
 

























5. For usual clinical scenarios in patients who are not critically ill, ensure that selection
guidelines target for the "norm," rather than for rare or unlikely events.
• Choose antibiotics with the narrowest spectrum and least cost possible.
6. For critically ill patients, ensure that selection guidelines permit broad spectrum
coverage of antibiotic resistant pathogens based on local susceptibility patterns.
7. Ensure facility guidelines make antibiotic susceptibility patterns and the cost of











1. Develop standard order sets/pathways for common infections that clearly specify
appropriate time from ordering to administration and monitor adherence to these
standards. 
• Consider signage in the chart or room to specify the time by which antibiotics
must be given.  
2. Develop a system for ensuring prompt treatment of patients transferred from the ED
to the ICU or ward.
3. Identify patients experiencing delays in antibiotic ordering and administration and
assess and address delay-prone aspects of the system. 
4. Define a process to expedite decision making when attending physician is not 





1. Follow the delivery chain from order to pharmacy and back again to ascertain where
efficiencies can be gained.
2. Consider keeping frequently used antibiotics available in the ED and on the flooriv . 
Specify Incorporate 1. Develop evidence-based clinical pathways that standardize the duration of
expected evidence- treatment.  
duration of based 2. Permit physicians to opt out of the standard duration of treatment, but require
therapy based guidelines for documentation of the rationalev . 
on evidence duration of 3. Consider a system for automatically discontinuing antibiotics based on national and
and national antibiotics into facility guidelines e.g. after 24 hours (surgical prophylaxis).  







5. Utilize the EHR with clinical decision support functionality to establish appropriate
duration.
6. Reassess the need for and prescribed duration of antibiotics daily and at all
transitions in care.
7 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
     

























   
  
   
 
   
    
 
   
   
  












    
 
   
  
   
    
     
  
     
     
    































Specific Change Ideas 
Make Ensure a clear 1. Define a prominent location in the medical record and at the bedside for
antibiotics history of patient antibiotic therapy to be documented (e.g., “this is day X of Y”) – this may
patient is antibiotic use is require modifications to the Medical Administration Record (MAR)





3. Use reminders in the EHR if this information is not complete.
point of care 4. Make sure start dates, stop dates and duration are also available in the
and in pharmacy electronic system and available for review.
electronic 5. Develop a system to ensure that antibiotic days are counted correctly (e.g., 
health does the first day of therapy count as day zero or day one?).
records 6. On admission, collect a complete list of the antibiotics a patient is taking (i.e., 
(EHR), as what antibiotic the patient is on, at what dose, when it was started).
applicable 7. When modifying antibiotics, establish system/mechanism to prevent a new
start date when 1
st
 regimen of AB is modified.  EHR may require specific
programming to do this properly.
Give Establish a 1. Imbed dose and interval in guidelines, clinical pathways, and order sets. 
antibiotics at process for (e.g. UTI) Make explicit the cases where pharmacy will do dosing.





infection, toxicity, and pharmacokinetic and pharmacodynamic
characteristics of the drug.
3. Ensure guidelines, pathways and order sets include alerts on when dose
adjustments might be indicated (e.g., for renal dysfunction).
4. Utilize the EHR with clinical decision support functionality to establish right
dose and interval.  
5. Establish a mechanism for pharmacy to review cases where dose
adjustments might be indicated (e.g., in patients with renal dysfunction, or
when more toxic agents like aminoglycosides are prescribed).   Include a
reminder system to pharmacy to identify appropriate patients. 
Stop or de- Establish process 1. Standardize the notification process by setting a time frame within which
escalate
vi for prompt culture results must be reported and to whom.   





3. Develop list of "critical results"/positive cultures to report to the physician via
based on the susceptibility page or automated means such as a text message (e.g., MDRO). 
culture and results
vii 
• Ensure that the reporting system includes mechanisms to alert 
sensitivity responsible clinical staff when the attending physician is unavailable; 
results • Develop and monitor a standard timeframe for reporting and receiving
critical results.
8 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
     






















     
























   
   
  
                      
         
           
                        
 
                
  
                      
   
   
 












   
 
     
   
  











Specific Change Ideas 
Stop or de- Stop or de­ 4. Standardize the process for  discontinuing antibiotics:
escalatevi escalate • When positive cultures most likely represent colonization rather than
therapy antibiotic based infection.
promptly on culture result • If cultures are negative or alternative non-infectious agent is diagnosed in
based on the
48 to 72 hours.  Permit physicians to opt out of automatically discontinuing
antibiotics based on negative culture results, but require documentation of
culture and the rationale.
sensitivity 5. If indication for antibiotics is clearly identified, de-escalate therapy to target 
results the susceptibilities of the pathogen.
(Continued) 6. Standardize all hand offs to include review of culture results or pending
culture results, antibiotic duration, and current plans for antibiotic
discontinuation.
7. Include de-escalation guidelines in standard pharmacy training.
Reconcile and Look for all 1. Utilize every Multi-Disciplinary Round (MD) and transition in care to ensure:
adjust opportunities to • Antibiotic matches pathogen and sensitivity;
antibiotics, at stop or change • The dose and dose interval are correct given current clinical status 
all transitions






• Appropriate toxicity monitoring is occurring; 





• Opportunities for discontinuation or de­escalation in therapy are 
considered; 
• Whether patient can be converted from intravenous to oral (IV to 
PO) antibiotics. 
2. Consider an “antibiotic time out” to support reconciling and adjusting
antibiotics.
3. Pay special attention to antibiotic duplication on conversion day.
Monitor for Ensure 1. Ensure a reliable process to monitor for antibiotic toxicity and promptly adjust 
toxicity appropriate agent and dose.
reliably and monitoring and • Facility antibiotic guidelines, order sets, and pathways should include
adjust agent adjustment of information on what toxicity monitoring should occur for the recommended
and dose agent antibiotic(s). 
promptly • Consider developing specific guidelines/pathways/order sets to ensure
proper toxicity monitoring of more toxic agents (e.g., aminoglycosides).
2. Select antibiotics that maximize therapeutic impact while minimizing toxicity.
9 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
  
   



























   
  
   
     
    
   
 
 
    
    
    
  
    
  
  
   
 
   
 
  
   
    
  
  
   
     
   







































1. Develop a process for ongoing monitoring and measurement of:
• Antibiotic utilization and resistance patterns; 
• C. difficile rates. 
• Costs associated with antibiotic use
• Process measures for timely and appropriate initiation of antibiotics
• Process measures for appropriate administration and de-escalation
2. Using these measures, report a “family of measures” for antibiotic
stewardship to senior leadership on a monthly basis:
• include measure of cost 
• present data in time series chart to show trends
• annotate charts with information on the stewardship program
3. Develop a way to communicate local and hospital data on antibiotic
susceptibility patterns.
• Inform antibiotic formulary selections based on local and hospital
susceptibility patterns.
4. Develop a mechanism for systematically reviewing antibiotic selection and
administration and influencing physician choice based on behavior science
principles, including but not limited toviii: 
• Prospective audit and feedback of adherence to hospital standards with
peer benchmarking;
• “Academic detailing”;
• Education targeted at continuing medical education and maintenance of
certification requirements; 
• Mobilization of local opinion leaders and change agents; 
• One-on-one mentoring of non-adherent physicians about antibiotic use
and evidence-based care.
5. Develop a mechanism to provide visible and ongoing feedback:
• Prominently post data on ADEs, C. difficile rates, antibiotic utilization, and
resistance patterns where all hospital staff can see;
• Provide direct feedback data to prescribers on their antibiotic use, 
including cost;
• Provide staff with feedback about antibiotic compliance using posters, 
email, newsletters, etc.;
• Consider making data on utilization, resistance, and ADEs available in
public areas to inform and educate patients and families about the
importance and role of antibiotic usage.
• Ensure the C-suite and CFO understand the rationale and results of the
program to support it financially.
10 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
 
















     
 
  
     
 
   

























     
    
  
   
  
    
 
     
  
       
     
   
  
 
   
 
    
    
  
 
   

















1. Improve antibiotic knowledge of clinical staff, including hospitalists, 
nurses, physician assistants, nurse practitioners, etc. (e.g., ordering of
cultures, antibiotic spectra). 
2. Develop and make available expertise in pharmacology (i.e., 
pharmacokinetics and pharmacodynamics) and antibiotic spectrum and
activity, and ensure that such expertise is available to clinicians at the
point of care.
3. Consider developing short, targeted educational messages, ideally
based on local issues, that can be disseminated on a regular basis (e.g.,
monthly).  
4. Develop and disseminate key antibiotic use messages to facility staff
using a variety of mechanisms, depending on resources (e.g., posters, 
emails, meeting announcements, posters, academic detailing etc). 




1. Designate a group to make decisions about the facility antimicrobial
formulary (e.g., P&T committee, antimicrobial subcommittee). 
2. Develop formal criteria for use of defined antibiotics as a guide for use
by pharmacists on the floor. 
3. Consider developing criteria for use or requiring prior approval for the
use of certain antibiotics, e.g., those that are “last lines of defense,”
highly toxic or very expensive.











1. In hospitals with extensive clinical pharmacist support, develop protocols
for pharmacists to directly intervene at the point of care to improve
selection and administration of antibiotics.  
• Consider antibiotic alerts in clinical decision support systems with
guidance on defined antibiotics. 
2. In hospitals without extensive clinical pharmacist and infectious disease
specialist support:
• Develop a system to have access to clinical pharmacist and infectious
disease experts for consultations in complex situations;   
• Consider shared or virtual expertise in settings where infectious
disease and/or clinical pharmacists are not available in house;
• Develop training for staff pharmacists to enhance their ability to
support antibiotic therapy at the point of care. 
3. In academic centers, ensure that infectious disease fellows are fully
trained and competent to provide advice at the point of care or virtually, 
including on nights and weekends. 
4. In facilities where ID consultation is available, consider developing
criteria for situations where ID consultation is strongly recommended
(e.g., complicated infections, prior to placing PICC lines for home IV
antibiotics).
5. Develop a process for real time decision support at the point of care.
6. Create a structure for validating competency across disciplines 
and roles.
11 July 2012 Update Antibiotic Stewardship Drivers and Change Package | Prepared by the Institute for Healthcare Improvement
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Notes:
i
 “Antibiotic” is used throughout the change package to support specific efforts to improve patient care and
decrease costs related to antibiotic utilization.  Appropriate use of other antimicrobials, such as antifungal
agents, should also be considered.
ii
 Clinical pathways are used throughout the change package as a method for translating clinical practice
guidelines into a clear paper or computerized document specifying key actions that need to be performed
at specific times.  These pathways are intended to provide real-time decision support at the point of care
to facilitate implementation of evidence-based guidelines. They should be developed with multi­
disciplinary input to ensure that providers can utilize them within their normal work flow.  Three key
components of successful pathways include:
1. 	 Clearly specified key evidence-based actions;
2. 	 Timing of these actions; and
3. 	 Documentation of deviations or variations in care, including opt-out provisions.
iii
“Double coverage” or “combination therapy” refers to the practice of intentionally administering antibiotics
with overlapping spectra of activity.
iv 
Consider keeping frequently used antibiotics available in the ED and on the floor.
It is important that antibiotics stored at the point of care—in the ED or the OR—are maintained and
restocked.  Ensure that there is documentation of administration of antibiotics obtained from local stocks.  
v
 Two standard opt-out provisions to allow for provider discretion are:
1. 	 Permit physicians to opt out of the standard duration of treatment, but require documentation of
the rationale whenever prescribing against evidence-based guidelines; 
2. 	 Permit physicians to opt out of automatically discontinuing therapy based on local policy (e.g., 
prophylactic antibiotics for surgery), but require documentation of the rationale.
vi
 De-escalation refers to the practice of changing to more targeted therapy and/or discontinuing empirical
therapy based on clinical criteria and culture results.
vii 
Establish process for prompt notification of culture and antibiotic susceptibility results.
For the purposes of this change package “cultures” is being used as a general term that reaches beyond
the strictest definition to include results of rapid diagnostic tests, including viral tests. 
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